Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705108 | 0.82 | FOLH1 (0.44) | FOLH1ALBNPY4RNPY1RNPY5R | |
| SCHEMBL13311819 | 0.80 | SIRT5 (0.48) | FOLH1ALBNPY4RNPY1RNPY5R | |
| SCHEMBL26504875 | 0.80 | FOLH1 (0.48) | FOLH1ALB | |
| SCHEMBL14300277 | 0.80 | FOLH1 (0.44) | FOLH1ALDH1A1 | |
| SCHEMBL29300452 | 0.79 | NOD1 (0.45) | FOLH1ALB | |
| SCHEMBL29299817 | 0.78 | FOLH1 (0.45) | FOLH1ALBNPY4RNPY1RNPY5R | |
| SCHEMBL20133399 | 0.78 | QRFPR (0.43) | FOLH1QRFPR | |
| SCHEMBL6664909 | 0.78 | FOLH1 (0.53) | FOLH1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16322720 | 0.77 | FOLH1 (0.48) | FOLH1ALBALDH1A1 | |
| SCHEMBL15295145 | 0.77 | FOLH1 (0.49) | FOLH1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639373-B2 | Therapeutic and diagnostic agents for cancer | Technische Universität München (DE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639373-B2 | Therapeutic and diagnostic agents for cancer | CXCR4, CXCL12, CXCR3 | FOLH1 87/4885ALB 4419/4885NPY4R 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.